Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma

PharmacoEconomics

Volumn 28, Issue 7, 2010, Pages 577-584

  Zbrozek, Arthur S ^a   Hudes, Gary ^b   Levy, Donna ^a   Strahs, Andrew ^a   Berkenblit, Anna ^a   DeMarinis, Robert ^a   Parasuraman, Shreekant ^a  

^a PFIZER INC   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Interferon alpha, therapeutic use; Quality of life; Renal cell carcinoma, treatment; Temsirolimus, therapeutic use; Utility measurement

Indexed keywords

ALPHA INTERFERON; TEMSIROLIMUS;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH CARE QUALITY; HEALTH STATUS; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TOXICITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SIROLIMUS; YOUNG ADULT;

EID: 77953723676     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11535290-000000000-00000     Document Type: Article

References (23)

1. American Cancer Society. Cancer facts and figures 2009. Atlanta (GA): American Cancer Society [online]. Available from URL: http://www.cancer.org/ downloads/STT/500809 web.pdf [Accessed 2010 Mar 3]
2. Centers for Disease Control and Prevention. National hospital discharge survey. 2004. Atlanta (GA): CDC [online]. Available from URL: http://www.cdc.gov/nchs/nhds.htm. [Accessed 2009 Nov 9]
3. Centers for Disease Control and Prevention. Ambulatory health care data. 2004. Atlanta (GA): CDC [online]. Available from URL: http://www.cdc.gov/nchs/ ahcd.htm [Accessed 2009 Mar 3]
4. US Department of Health and Human Services. National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda (MD): US Department of Health and Human Services [online]. Available from URL: http://www.niddk. nih.gov [Accessed 2009 Nov 9]
5. McDermott D, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141
6. Negrier S, Escudier B, Lassett C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1272-1278
7. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl JMed 2007; 356: 125-134
8. Motzer R, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 256: 115-124
9. Hudes GR, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281
10. Escudier B, Plizanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111
11. Motzer R, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456
12. National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). Bethesda (MD): National Cancer Institute, 2006 [online]. Available from URL: http:// ctep.cancer.gov/protocolDevelopment/electronic- applications/ docs/ctcaev3.pdf [Accessed 2010 Mar 3]
13. Dolan P, Gudex C. Time preference, duration and health state preferences. Health Econ 1995; 4: 289-299
14. Cole BF, Gelber RD, Gelber S, et al. A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat 2004; 14: 111-124
15. Gelber RD, Cole BF, Goldhirsch A. Comparing treatments using quality-adjusted survival: the Q-TWiST method. Am Stat 1995; 49: 161-169
16. Glasziou PP, Cole BF, Gelber RD, et al. Quality adjusted survival analysis with repeated quality of life measures. Stat Med 1998; 17: 1215-1229
17. Revicki DA, Feeny D, Hunt TL, et al. Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res 2006; 15: 411-423
18. Zhao H, Tsistis A. A consistent estimator for the distribution of quality adjusted survival time. Biometrika 1997; 84: 339-348
19. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990; 9: 1259-1276
20. Radice D, Redaeli A. Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer. Pharmacoeconomics 2005; 23 (1): 69-75
21. Sherrill B, Amonkar MM, Stein S, et al. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008; 99: 711-715
22. Cella D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev 2009; 35 (8): 733-737
23. Yang S, Hudes G, de Souza P, et al. Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial [abstract no. P-7134]. Eur J Cancer Supplements 2009; 7: 433